2019
DOI: 10.12968/bjon.2019.28.18.1180
|View full text |Cite
|
Sign up to set email alerts
|

Recognising and understanding cryopyrin-associated periodic syndrome in adults

Abstract: Cryopyrin-associated periodic syndrome (CAPS) is a group of rare hereditary autoinflammatory diseases characterised by recurrent flares of mild to severe systemic inflammation and fever. CAPS is the umbrella term for a spectrum of individual conditions, namely familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurologic, cutaneous and articular (CINCA) syndrome. The flare symptoms include feve… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 20 publications
0
2
0
Order By: Relevance
“…There have been many immunomodulatory agents that have been investigated for off-label use for immune-mediated hearing loss. Inhibitors of IL-1 (anakinra, canakinumab, rilonacept) [36,38,70,82 ▪ ,83,84 ▪ ,85,86], IL-6 (tocilizumab) [87,88], TNF-α (infliximab, etanercept, golimumab, adalimumab) [34,42,67,69,74 ▪ ,88,89 ▪ ,90 ▪ ,91] and B-cells (rituximab) [34,67,69,88,93,94] have demonstrated efficacy. In addition, JAK inhibitors (tofacitinib) have recently been utilized in the treatment of autoimmune and autoinflammatory disorders [95 ▪ ].…”
Section: Discussionmentioning
confidence: 99%
“…There have been many immunomodulatory agents that have been investigated for off-label use for immune-mediated hearing loss. Inhibitors of IL-1 (anakinra, canakinumab, rilonacept) [36,38,70,82 ▪ ,83,84 ▪ ,85,86], IL-6 (tocilizumab) [87,88], TNF-α (infliximab, etanercept, golimumab, adalimumab) [34,42,67,69,74 ▪ ,88,89 ▪ ,90 ▪ ,91] and B-cells (rituximab) [34,67,69,88,93,94] have demonstrated efficacy. In addition, JAK inhibitors (tofacitinib) have recently been utilized in the treatment of autoimmune and autoinflammatory disorders [95 ▪ ].…”
Section: Discussionmentioning
confidence: 99%
“…Other typical signs and symptoms of CAPS include dermatological (urticarial-like rash), musculoskeletal (arthralgia, arthritis, myalgia, limb-length discrepancies and contractures, clubbing, patellar overgrowth), ocular (conjunctivitis, uveitis, papilledema, progressive amaurosis), and inner ear (sensorineural hearing loss) manifestations [ 18 ]. However, fever is not a common presenting symptom in patients with CAPS, and body temperature does not meet the standard criteria for fever [ 16 ].…”
Section: Cryopyrin-associated Periodic Syndromes: Nlrp3 ...mentioning
confidence: 99%